Please ensure Javascript is enabled for purposes of website accessibility
New Studies Clarify What Drugs Help, Hurt for COVID-19
gvw_ap_news
By Associated Press
Published 4 years ago on
July 19, 2020

Share

Fresh studies give more information about what treatments do or don’t work for COVID-19, with high-quality methods that give reliable results.
British researchers on Friday published their research on the only drug shown to improve survival — a cheap steroid called dexamethasone. Two other studies found that the malaria drug hydroxychloroquine does not help people with only mild symptoms.
For months before studies like these, learning what helps or harms has been undermined by “desperation science” as doctors and patients tried therapies on their own or through a host of studies not strong enough to give clear answers.
“For the field to move forward and for patients’ outcomes to improve, there will need to be fewer small or inconclusive studies” and more like the British one, Drs. Anthony Fauci and H. Clifford Lane of the National Institutes of Health wrote in the New England Journal of Medicine.
It’s now time to do more studies comparing treatments and testing combinations, said Dr. Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center in New York.
Here are highlights of recent treatment developments:

Dexamethasone

The British study, led by the University of Oxford, tested a type of steroid widely used to tamp down inflammation, which can become severe and prove fatal in later stages of COVID-19.
About 2,104 patients given the drug were compared to 4,321 patients getting usual care.
It reduced deaths by 36% for patients sick enough to need breathing machines: 29% on the drug died versus 41% given usual care. It curbed the risk of death by 18% for patients needing just supplemental oxygen: 23% on the drug died versus 26% of the others.
However, it seemed harmful at earlier stages or milder cases of illness: 18% of those on the drug died versus 14% of those given usual care.
The clarity of who does and does not benefit “probably will result in many lives saved,” Fauci and Lane wrote.

Hydroxychloroquine

The same Oxford study also tested hydroxychloroquine in a rigorous manner and researchers previously said it did not help hospitalized patients with COVID-19.
After 28 days, about 25.7% on hydroxychloroquine had died versus 23.5% given usual care — a difference so small it could have occurred by chance
Now, details published on a research site for scientists show that the drug may have done harm. Patients given hydroxychloroquine were less likely to leave the hospital alive within 28 days — 60% on the drug versus 63% given usual care. Those not needing breathing machines when they started treatment also were more likely to end up on one or to die.
Two other experiments found that early treatment with the drug did not help outpatients with mild COVID-19.
study of 293 people from Spain published in the journal Clinical Infectious Diseases found no significant differences in reducing the amount of virus patients had, the risk of worsening and needing hospitalization, or the time until recovery.
A similar study by University of Minnesota doctors in Annals of Internal Medicine of 423 mildly ill COVID-19 patients found that hydroxychloroquine did not substantially reduce symptom severity and brought more side effects.
“It is time to move on” from treating patients with this drug, Dr. Neil Schluger from New York Medical College wrote in a commentary in the journal.

Photo of hydroxychloroquine tablets
FILE – In this April 9, 2020 file photo, a chemist displays hydroxychloroquine tablets in New Delhi, India. U.S. regulators are revoking emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19. The Food and Drug Administration said Monday, June 15 that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. (AP Photo/Manish Swarup, File)

Remdesivir

The only other therapy that’s been shown to help COVID-19 patients is remdesivir, an antiviral that shortens hospitalization by about four days on average.
“The role of remdesivir in severe COVID is now what we need to figure out,” Memorial Sloan Kettering’s Bach wrote in an email, saying the drug needs to be tested in combination with dexamethasone now.
Details of the government-led remdesivir study have not yet been published, but researchers are eager to see how many patients received other drugs such as steroids and hydroxychloroquine.
Meanwhile, Gilead Sciences, the company that makes remdesivir, which is given as an IV now, has started testing an inhaled version that would allow it to be tried in less ill COVID-19 patients to try to keep them from getting sick enough to need hospitalization. Gilead also has started testing remdesivir in a small group of children.
Supplies are very limited, and the U.S. government is allocating doses to hospitals through September.

Photo of a vial of the investigational drug remdesivir
In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)

DON'T MISS

What to Know About Pam Bondi, Trump’s New Pick for Attorney General

DON'T MISS

North Korean Leader Says Past Diplomacy Only Confirmed US Hostility

DON'T MISS

Democrats Strike Deal to Get More Biden Judges Confirmed Before Congress Adjourns

DON'T MISS

Newsom Gaslights on Potential Gas Price Hikes in Fresno Visit

DON'T MISS

Automakers to Trump: Please Require Us to Sell Electric Vehicles

DON'T MISS

President Biden Welcomes 2024 NBA Champion Boston Celtics to White House

DON'T MISS

Ohtani Makes History With 3rd MVP, Judge Claims 2nd AL Honor

DON'T MISS

Trump Chooses Pam Bondi for Attorney General Pick After Gaetz Withdraws

DON'T MISS

Average Rate on a 30-Year Mortgage in the US Rises to Highest Level Since July

DON'T MISS

Cutting in Line? American Airlines’ New Boarding Tech Might Stop You at Now Over 100 Airports

UP NEXT

Bomb Cyclone Kills 1 and Knocks Out Power to Over Half a Million Homes Across the Northwest US

UP NEXT

Volunteers Came Back to Nonprofits in 2023, After the Pandemic Tanked Participation

UP NEXT

New Study: Proposed Trump Tariffs Could Cost US Consumers $78 Billion a Year

UP NEXT

Riders Stuck in Midair for Over 2 Hours on Knott’s Berry Farm Ride

UP NEXT

Shouting Racial Slurs, Neo-Nazi Marchers Shock Ohio’s Capital

UP NEXT

More Logging Is Proposed to Help Curb Wildfires in the US Pacific Northwest

UP NEXT

Scientists Fear What’s Next for Public Health if RFK Jr. Is Allowed To ‘Go Wild’

UP NEXT

Warren Slams Biden Admin for Failing to Hold Israel Accountable on Gaza Aid

UP NEXT

Suicides in the US Military Increased in 2023, Continuing a Long-Term Trend

UP NEXT

New FDA Rules for TV Drug Ads: Simpler Language and No Distractions

Newsom Gaslights on Potential Gas Price Hikes in Fresno Visit

8 hours ago

Automakers to Trump: Please Require Us to Sell Electric Vehicles

8 hours ago

President Biden Welcomes 2024 NBA Champion Boston Celtics to White House

8 hours ago

Ohtani Makes History With 3rd MVP, Judge Claims 2nd AL Honor

9 hours ago

Trump Chooses Pam Bondi for Attorney General Pick After Gaetz Withdraws

9 hours ago

Average Rate on a 30-Year Mortgage in the US Rises to Highest Level Since July

10 hours ago

Cutting in Line? American Airlines’ New Boarding Tech Might Stop You at Now Over 100 Airports

10 hours ago

MLB Will Test Robot Umpires at 13 Spring Training Ballparks Hosting 19 Teams

10 hours ago

Death Toll in Gaza From Israel-Hamas War Passes 44,000, Palestinian Officials Say

10 hours ago

Jussie Smollett’s Conviction in 2019 Attack on Himself Is Overturned

10 hours ago

What to Know About Pam Bondi, Trump’s New Pick for Attorney General

NEW YORK — Pam Bondi, the former Florida attorney general, was chosen Thursday by Donald Trump to serve as U.S. attorney general hours after...

6 hours ago

6 hours ago

What to Know About Pam Bondi, Trump’s New Pick for Attorney General

7 hours ago

North Korean Leader Says Past Diplomacy Only Confirmed US Hostility

7 hours ago

Democrats Strike Deal to Get More Biden Judges Confirmed Before Congress Adjourns

8 hours ago

Newsom Gaslights on Potential Gas Price Hikes in Fresno Visit

President Joe Biden with Mary Barra, the chief executive of General Motors, at the Detroit Auto Show, Sept. 14, 2022. President-elect Donald Trump has promised to erase the Biden administration’s tailpipe rules designed to get carmakers to produce electric vehicles, but most U.S. automakers want to keep them. (Doug Mills/The New York Times)
8 hours ago

Automakers to Trump: Please Require Us to Sell Electric Vehicles

8 hours ago

President Biden Welcomes 2024 NBA Champion Boston Celtics to White House

9 hours ago

Ohtani Makes History With 3rd MVP, Judge Claims 2nd AL Honor

Former Florida Attorney General Pam Bondi, speaks before Republican presidential nominee former President Donald Trump arrives to speak at a campaign rally at First Horizon Coliseum, Saturday, Nov. 2, 2024, in Greensboro, NC. (AP/Alex Brandon)
9 hours ago

Trump Chooses Pam Bondi for Attorney General Pick After Gaetz Withdraws

Help continue the work that gets you the news that matters most.

Search

Send this to a friend